DE570357T1 - Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren. - Google Patents

Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.

Info

Publication number
DE570357T1
DE570357T1 DE0570357T DE93890100T DE570357T1 DE 570357 T1 DE570357 T1 DE 570357T1 DE 0570357 T DE0570357 T DE 0570357T DE 93890100 T DE93890100 T DE 93890100T DE 570357 T1 DE570357 T1 DE 570357T1
Authority
DE
Germany
Prior art keywords
peptides according
seq
peptides
fusion
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0570357T
Other languages
German (de)
English (en)
Inventor
Gottfried A-1180 Vienna Himmler
Hermann A-1190 Vienna Katinger
Georg A-1040 Vienna Maiwald
Thomas A-1180 Vienna Muster
Martin A-1180 Vienna Purtscher
Florian A-1170 Vienna Rueker
Franz A-1160 Vienna Steindl
Alexandra A-1232 Vienna Trkola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymun Scientific Immunbiologische Forschung GmbH
Original Assignee
Polymun Scientific Immunbiologische Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT98792A external-priority patent/AT403050B/de
Application filed by Polymun Scientific Immunbiologische Forschung GmbH filed Critical Polymun Scientific Immunbiologische Forschung GmbH
Publication of DE570357T1 publication Critical patent/DE570357T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE0570357T 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren. Pending DE570357T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT98792A AT403050B (de) 1992-05-14 1992-05-14 Peptide, die antikörper binden
US93278792A 1992-08-29 1992-08-29

Publications (1)

Publication Number Publication Date
DE570357T1 true DE570357T1 (de) 1994-07-28

Family

ID=25594514

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0570357T Pending DE570357T1 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
DE69311764T Expired - Lifetime DE69311764T2 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69311764T Expired - Lifetime DE69311764T2 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren

Country Status (6)

Country Link
US (3) US5693752A (OSRAM)
EP (1) EP0570357B1 (OSRAM)
JP (1) JP3369246B2 (OSRAM)
CA (1) CA2096159C (OSRAM)
DE (2) DE570357T1 (OSRAM)
ES (1) ES2053413T3 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018540A1 (en) * 1991-04-18 1992-10-29 Mount Sinai School Of Medicine Of The City University Of New York Anti-human immunodeficiency virus recombinant antibodies
CA2096159C (en) * 1992-05-14 2004-07-20 Hermann Katinger Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates
BR9407531A (pt) * 1993-09-11 1997-08-26 Polymun Scient Immunbio Forsch Peptideos que provocam a formação de anticorpos neutralizadores contra cepas de HIV-1 geneticamente divergentes
US6399294B1 (en) 1994-10-20 2002-06-04 Institut Pasteur Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
ES2178672T3 (es) * 1995-04-19 2003-01-01 Polymun Scient Immunbio Forsch Anticuerpos monoclonales frente al vih-1 y vacunas hechas a partir de ellos.
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
EP1098961B1 (en) 1998-06-12 2008-01-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
SK288544B6 (sk) * 1998-06-12 2018-03-05 Mount Sinai School Of Medicine Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie
JP4637356B2 (ja) * 1998-08-04 2011-02-23 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 広い反応性の中和抗体応答を伴うｈｉｖ−１エンベロープタンパク質の発現およびキャクタライゼーション
US7090848B1 (en) 1998-08-04 2006-08-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
WO2001077394A1 (en) * 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US7625566B2 (en) 2002-01-17 2009-12-01 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic monoclonal antibody reactive with HIV neutralizing antibody 2F5
WO2004101738A2 (en) * 2003-05-06 2004-11-25 The Scripps Research Institute Domain-exchanged binding molecules, methods of use and methods of production
CA2610632C (en) 2004-06-01 2022-10-04 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
JP2008535783A (ja) 2005-02-15 2008-09-04 サイモン・エル・エル・シー Ｈｉｖ−１の増殖を弱めるための方法および組成物
US8137676B2 (en) * 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
TW200726479A (en) * 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
CA2683752A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
JP7678790B2 (ja) 2019-07-15 2025-05-16 ローザンヌ ユニヴァーシティ ホスピタル Ｈｉｖ結合剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU617088B2 (en) * 1986-06-12 1991-11-21 Biogen, Inc. Peptides involved in the pathogenesis of hiv infection
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
EP0362910A3 (en) * 1988-08-27 1991-01-09 Akzo N.V. Synthetic peptides immunochemically reactive with hiv-antibodies
CA2096159C (en) * 1992-05-14 2004-07-20 Hermann Katinger Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates

Also Published As

Publication number Publication date
US5866694A (en) 1999-02-02
CA2096159C (en) 2004-07-20
EP0570357B1 (en) 1997-06-25
JP3369246B2 (ja) 2003-01-20
US5756674A (en) 1998-05-26
DE69311764T2 (de) 1998-02-05
DE69311764D1 (de) 1997-07-31
CA2096159A1 (en) 1993-11-15
ES2053413T3 (es) 1997-11-16
JPH06293797A (ja) 1994-10-21
US5693752A (en) 1997-12-02
EP0570357A3 (OSRAM) 1994-04-20
ES2053413T1 (es) 1994-08-01
EP0570357A2 (en) 1993-11-18

Similar Documents

Publication Publication Date Title
DE570357T1 (de) Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
KR900701836A (ko) 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드
RU95122726A (ru) Способ получения иммуногенов или диагностических реагентов, а также иммуногены и диагностические реагенты, получаемые с его помощью
ATE175121T1 (de) Durch pre-s-gen kodierte hepatitis-b-peptid- immunogene, vakzine, diagnostika und synthetische lipid-bläschenträger
CN111732654B (zh) 一种抗SARS-CoV-2的单克隆抗体1E10
MX347175B (es) Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central.
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
EP0291636A1 (en) Immune response to viruses induced by anti-idiotype antibodies
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途
DE69223250T3 (de) Detektion des immunschwäche-virus aus felis
EP1331271A4 (en) POLYPEPTIDE FRAGMENT OF HEPATITIS E VIRUS, VACCINE COMPOSITION CONTAINING SAID FRAGMENT, DIAGNOSTIC AGENT AND THEIR APPLICATIONS
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
RU96108781A (ru) Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1
ATE136933T1 (de) Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe
DE69814884T2 (de) Hepatitis b virale polypeptide
DE69106141T2 (de) Non-a non-b sequenzen.
WO1996009391A3 (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
DE3887521T2 (de) Durch virusneutralisierende und schützende monokonale antikörper erkanntes ibdv vp2 epitop.
DE69200512T2 (de) Mit Antikörper gegen Hepatitis non-A, non-B-Virus immunochemische reaktive Peptide.
DE68926813T2 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
Hopp Computer prediction of protein surface features and antigenic determinants
AU619477B2 (en) Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies
EP0419446B1 (de) Komplex geeignet zur Durchführung eines Verfahrens zur Reinigung von pre-S-Hepatitis-B-Virus-Oberflächenantigen
ATE79638T1 (de) Polypeptide, deren kodierende peptide und methode zur herstellung dieser peptide und dnas.
US20060275309A1 (en) Peptide oligomers for use as hiv vaccines